SCHEMBL5544295

SCHEMBL5544295

CCCCCCOCCOCCO[C]=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
THRB P10828 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPT P10636 1/20 0.54
CES2 O00748 2/20 0.45
TSHR P16473 2/20 0.42
CYP3A4 P08684 1/20 0.42
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
USP2 O75604 1/20 0.38
CA1 P00915 6/20 0.38
CA2 P00918 6/20 0.38
CA9 Q16790 6/20 0.38
LPAR3 Q9UBY5 3/20 0.38
LPAR1 Q92633 2/20 0.38
LPAR2 Q9HBW0 2/20 0.38
CA12 O43570 2/20 0.38
CA3 P07451 2/20 0.38
CA4 P22748 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8362606 1.00 MEN1 (0.54) MEN1THRBHTTKMT2AMAPT
SCHEMBL5482902 1.00 MEN1 (0.54) MEN1THRBHTTKMT2AMAPT
SCHEMBL6759184 1.00 MEN1 (0.54) MEN1THRBHTTKMT2AMAPT
SCHEMBL5428085 0.98 MEN1 (0.50) MEN1THRBHTTKMT2AMAPT
SCHEMBL5539506 0.98 MEN1 (0.50) MEN1THRBHTTKMT2AMAPT
SCHEMBL7209213 0.91 MEN1 (0.48) MEN1THRBHTTKMT2AMAPT
SCHEMBL5540017 0.91 TSHR (0.50) MEN1THRBHTTKMT2AMAPT
SCHEMBL1190989 0.91 TSHR (0.50) MEN1THRBHTTKMT2AMAPT
SCHEMBL7249899 0.89 MEN1 (0.45) MEN1THRBHTTKMT2AMAPT
SCHEMBL7252397 0.89 MEN1 (0.45) MEN1THRBHTTKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MEN1 3295/4885THRB 488/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.